Fahad Khan, MD
Glaucoma Specialist · San Diego, CANPI 1548605843
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,907 of the $5,407 with a category attached, or 72.3%. 18 manufacturers reported payments, led by Glaukos Corporation at 36.8% of the total. Reporting peaked in 2021 at $2,622 and has fallen 90.3% since, to $256 in 2024.
Across 84 payments — averaging $64.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Alcon$1K
- AbbVie$735
- Aerie Pharmaceuticals, Inc.$465
- Bausch & Lomb, A Division Of Bausch Health US, LLC$256
- Johnson & Johnson Surgical Vision, Inc.$174
- plus $726 from 12 others
What the payments were for
- Speaking & faculty fees$1,50028%
- Food & beverage$3,90772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 13 | $1,989 |
| Alcon | 16 | $1,062 |
| AbbVie(2 entities) | 19 | $735 |
| Aerie Pharmaceuticals, Inc. | 8 | $465 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $256 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $174 |
| Kala Pharmaceuticals, Inc. | 3 | $155 |
| Ellexiscience | 1 | $147 |
| Sight Sciences, Inc. | 2 | $114 |
| Iridex Corporation | 1 | $63 |
| Abbott | 1 | $57 |
| Thea Pharma Inc. | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 3 | $43 |
| Ivantis, Inc | 1 | $32 |
| Rxsight Inc | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,407 in reported general payments places this provider in the 55th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 79 | $28,884 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $21,400 |
| VyzultaLatanoprostene Bunod | 13 | $8,317 |
| Alphagan PBrimonidine Tartrate | 26 | $5,097 |
| Prednisolone Acetate | 127 | $3,278 |
| MoxifloxacinMoxifloxacin Hcl | 113 | $3,048 |
| Brimonidine Tartrate | 41 | $2,439 |
| BetimolTimolol | 12 | $2,350 |
| Ketorolac Tromethamine | 99 | $1,266 |
| Latanoprost | 99 | $863 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $549 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 24 | $267 |
| Timolol Maleate | 15 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P | $735 | $33,981105 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $465 | $21,40039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in San Diego
- Cristiana VasileSan Diego$3K
- Andrew CampSan Diego$2K
- Ashkan KashanchiSan Diego$969
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.